Neuroimaging on Methamphetamine Users with Psychiatric Symptoms

  • Masaomi Iyo
  • Yoshimoto Sekine
  • Norio Mori
Part of the Advances in Behavioral Biology book series (ABBI, volume 53)


A long-term abuse of methamphetamine causes psychiatric symptoms, such as psychosis and anxiety disorder-like symptoms. Some of the symptoms are persistent for long time of period even after cessation of the methamphetamine use. We employed positron emission tomography (PET) studies to clarify the changes in the brain dopaminergic systems of methamphetamine abusers and the relations of the changes to their psychiatric symptoms. It was indicated that persistent reduction of dopamine transporter density in the caudate/putamen, nucleus accumbens and prefrontal cortex in the abusers, whereas the density of dopamine D2 receptors were not different from the control subjects. The results also suggested the reduction of dopamine transporter density may be closely associated with duration of methamphetamine use and severity of persistent psychiatric symptoms in methamphetamine users.


Positron Emission Tomography Psychiatric Symptom Psychotic State Methamphetamine User Methamphetamine Abuser 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    K. Konuma, S. Hirai, and M. Kasahara, in: Amphetamine and Its Analogs, edited by A. K. Cho and D. S. Segal (San Diego, Academic Press, 1994), pp. 459–478.Google Scholar
  2. 2.
    M. Sato, Y. Numach, and T. Hamamura, Relapse of paranoid psychotic state in methamphetamine model of schizophrenia. Schizophr. Bull. 18:115–122 (1992).PubMedCrossRefGoogle Scholar
  3. 3.
    B. Angrist, in: Amphetamine and Its Analogs, edited by A. K. Cho and D. S. Segal (San Diego, Academic Press, 1994), pp. 387–414.Google Scholar
  4. 4.
    P.A. LeDuc, G. Mittleman, Schizophrenia and psychostimulant abuse: a review and re-analysis of clinical evidence, Psychopharmacology. 121:407–427 (1995).PubMedCrossRefGoogle Scholar
  5. 5.
    J. M. Cleghorn, R. D. Kaplan, B. Szechtman, H. Szechtman, G. M. Brown, and S. Franco, Substance abuse and schizophrenia: effect on symptoms but not on neurocognitive function, J. Clin. Psychiatry. 52:26–30 (1991).PubMedGoogle Scholar
  6. 6.
    B. Kirkpatrick, X. F. Amador, M. Flaum, S. A. Yale, J. M. Gorman, W. T. Jr. Carpenter, M. Tohen, and T. McGlashan, The deficit syndrome in the DSM-IV field trial: I. Alcohol and other drug abuse, Schizophr. Res. 20:69–77 (1996).PubMedCrossRefGoogle Scholar
  7. 7.
    M. Iyo, M. Nishio, T. Itoh, H. Fukuda, K. Suzuki, T. Yamasaki, S. Fukui, and Y. Tateno, Dopamine D2 and serotonin S2 receptors in susceptibility to methamphetamine psychosis detected by PET, Psychiatry. Res. 50: 217–231 (1993).PubMedCrossRefGoogle Scholar
  8. 8.
    N. D. Volkow, J. S. Fowler, A. P. Wolf, D. Schlyer, C. Y. Shiue, R. Alpert, S. L. Dewey, J. Logan, B. Bendriem, D. Christman, R. Hitzemann, and F. Henn, Effects of chronic cocaine abuse on postsynaptic dopamine receptors. Am. J. Psychiatry. 147:719–724 (1990).PubMedGoogle Scholar
  9. 9.
    J. M. Wilson, K. S. Kalasinsky, A. I. Levey, C. Bergeron, G. Reiber, R. M. Anthony, G. A. Schmunk, K. Shannak, J. W. Haycock, and S. J. Kish, Striatal dopamine nerve terminal markers in human, chronic methamphetamine users, Nat. Med. 2:699–703 (1996).PubMedCrossRefGoogle Scholar
  10. 10.
    U. D. McCann, D. F. Wong, F. Yokoi, V. Villemagne, R. F. Dannals, and G. A. Ricaurte, Reduced striatal dopamine transporter density in abstinent methamphetamine and methcathinone users: Evidence from positron emission tomography studies with [11C]WIN-35, 428, J. Neurosci. 18:8417–8422 (1998).PubMedGoogle Scholar
  11. 11.
    Y Sekine, M. Iyo, Y Ouchi, T. Matsunaga, H. Tsukada, H. Okada, E. Yoshikawa, M. Futatsubashi, N. Takei, and N. Mori, Methamphetamine-Related Psychiatric Symptoms and Reduced Brain Dopamine Transporters Studied With PET, Am. J. Psychiatry. (August, 2001 in press).Google Scholar
  12. 12.
    A. Laakso, H. Vilkman, B. Alakare, M. Haaparanta, J. Bergman, O. Solin, J. Peurasaari, V. Rakkolainen, E. Syvalahti, and J. Hietala, Striatal dopamine transporter binding in neuroleptic-naive patients with schizophrenia studied with positron emission tomography, Am. J. Psychiatry. 157:269–271 (2000).PubMedCrossRefGoogle Scholar
  13. 13.
    P. Seeman, and H. B. Niznik, Dopamine receptors and transporters in Parkinson’s disease and schizophrenia, F. A. S. E. B. J. 4:2737–2744 (1990).Google Scholar

Copyright information

© Springer Science+Business Media New York 2002

Authors and Affiliations

  • Masaomi Iyo
    • 1
  • Yoshimoto Sekine
    • 2
  • Norio Mori
    • 2
  1. 1.GraduateSchool of MedicineChiba UniversityChibaJapan
  2. 2.Hamamatsu University School of MedicineHamamatsuJapan

Personalised recommendations